A kind of traditional Chinese medicine composition for treating pulmonary arterial hypertension and preparation method thereof

Abstract

The invention belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating pulmonary hypertension and a preparation method of the traditional Chinese medicine composition. The invention provides a traditional Chinese medicine composition capable of significantly lowering mean pulmonary arterial pressure and right ventricle hypertrophy index to overcome the defects in the prior art. The traditional Chinese medicine composition is mainly prepared from the following raw materials in parts by weight: 8-20 parts of centella asiatica, 5-15 parts of caulis spatholobi, 5-15 parts of salviae miltiorrhizae, 3-10 parts of coptis chinensis, 10-25 parts of cassia twig, 5-15 parts of flos carthami, 10-20 parts of wogonoside, 3-10 parts of red peony root, 10-20 parts of dried radix rehmanniae, 5-15 parts of ligusticum wallichii, 8-20 parts of mulberry leaves, 5-12 parts of rhizoma cimicifugae, 10-20 parts of bletilla striata, 3-10 parts of evening primrose, 5-15 parts of gardenia, 3-10 parts of pollen typhae, 3-10 parts of cenchrus echinatus, 5-12 parts of fructus arctii, 10-15 parts of morinda officinalis, 10-20 parts of uncaria rhynchophylla, 3-10 parts of herba epimedii, 5-15 parts of fructus evodiae, 5-15 parts of spina date seeds, 5-25 parts of rhizoma corydalis and 10-20 parts of liquorice. A pharmacological experiment and a clinical experiment prove that the traditional Chinese medicine composition has a significant treatment effect on pulmonary hypertension, so that the traditional Chinese medicine composition has wide medical popularization value.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating pulmonary hypertension and a preparation method thereof. Background technique [0002] Pulmonary hypertension (PH) has complex etiology and is caused by a variety of heart, lung or pulmonary vascular diseases. It is manifested by increased pulmonary circulation pressure and resistance, increased right ventricular load, right ventricular insufficiency, and reduced pulmonary blood flow, which can cause a series of clinical manifestations. Pulmonary hypertension often develops progressively during the course of the disease. It is a serious and potentially fatal chronic pulmonary circulation disease, especially idiopathic arterial pulmonary hypertension, which can only be diagnosed about 2 years after the onset of symptoms, and the natural course of the disease after diagnosis is mostly 2.5-3.4 years. [0...

AI Technical Summary

Problems solved by technology

Currently, traditional Chinese medicines used clinically have inaccurate curative effects on pulmonary arterial hypertension, especially long-term medication effects are not good. The present invention aims to provide a drug for treating pulmonary arterial hypertension with definite therapeutic effect and low treatment cost.